CTR057398_Donohue_and_Associate_-_Initial.pdf
PDF 9 MB Posted
- Attached to
- Master Agreement AZ|CTR057398
- Contract number
- CTR057398
- Issued by
- Arizona
About this file
Based on the provided document, this appears to be a fragmented contract file for Michael S. Donohue and Associates, potentially related to a pharmaceutical or healthcare services contract. The document contains multiple addenda and appears to be associated with a Board of Pharmacy Specialties (BPS) assessment, though specific jurisdictional details are limited in the provided excerpt.
The document includes supplementary materials such as drug interaction analysis from Lexicomp and UpToDate, and a detailed psychotropic medication utilization chart comparing state and national averages for 2019-2020. While comprehensive contract details are not fully visible, the document suggests involvement with pharmaceutical services, medication management, and potentially a state-level healthcare contract. The file includes payment records, with a noted payment of $125.00 for a "Maintenance Fee - Geriatric Pharmacy 2020" and a transaction ID of BPS-PMT-201050. Michael S. Donohue, Pharm.D. is listed as the President, indicating his leadership role in the referenced organization.
View the file
Other files
Show all 30
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Addendum 1
6/112020 A-1 Michael S Donohue BPS #IND-922931 bps aoard of PhormQO,J Specloltles®
Logged In: Michael S Doi
Payment Successful
Thank you. Your payment is complete and has been assigned the ID: BPS-PMT-201050. Please note this for future reference
The following payments were received/refunded:
Item Date Description
06/12/2020 Credit - Maintenance Fee - Geriatric Pharmacy
2 06/12/2020 Maintenance Fee - Geriatric Pharmacy 2020
We have also sent the payment receipt via email.
Amount
-12.50
125.00
Total: 112.50 https://portalbps.cyzap.neVdzapps/dbzap.bln/apps/assess/webmembers/seoure/manage?webidc:BPS&pToolCode=PMT&pAssessmentlD=&pSave=Ves
Addendum 2
A-2
Addendum 3
A-3
A-3A-3
A-3 A-3A-3
Addendum 4
A-4
A-4
Addendum 5
A-5
Addendum 6
4/5/2021
A-6
Lexicomp® Drug Interactions - UpToDale
Lexicomp® Drug Interactions
Item List
• SEROquel
• Escitalopram
• Levaqufn [DSC]
DSC: Discontinued brand (equivalent product[s] may be available)
NOTE: This tool does not address chemical compatibility related to 1.V. drug preparation or administration.
© 2021 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
CR] Avoid combination [[] Consider therapy modification
4 Results
CC "'] Monitor therapy l-A J No known interaction e·-1 No action needed
: Filter Results by Item v fc'I Escltalopram (QT-prolonging Antidepressants (Moderate Risk))/ Levaqufn [DSC] (QT-prolonging Quinolone
• Antibiotics (Moderate Risk))
!- �__] Escltalopram {QT-prolonging Antidepressants (Moderate Risk)) I SEROquel (QT-prolonging Antipsychotfcs (Moderate
• Risk))
• I [J SEROquel (Antipsychotic Agents)/ Escitalopram (Serotonergic Agents (High Risk))
[§'-] SEROquel (QT-prolonging Antipsychotics (Moderate Risk)) / Levaquin [DSC] (QT-prolonging Quinolone Antibiotics
• (Moderate Risk))
Disclaimer: Readers are advised that decisions regarding drug therapy must be based on the independent Judgment of the clinician, changing information about a drug (eg, as reflected in the literature and manufacturer's most currant product information), and changing medical practices.
https://www.uptodate.com/drug-interactions/?source=responsive_home#di-analyze 1/1
Addendum 7
Addendum 8
AA-8
\-8
Total Psychotropic Utilization
2019 2020 State Avg Nation Avg
Jan 63.1 69.7 57.9 64.7
Feb 62.8 72 57.9 64.7
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
66.5 72.8 57.9 64.7
65.8 76.4 57.9 64.7
78.8 57.9 64.7
78.2 57.9 64.7
80.7 57.9 64.7
74.5 57.9 64.7
74.3 57.9 64.7
70.9 57.9 64.7
76.9 57.9 64.7
72.6 57.9 64.7
I ., . ' • .._,, ,. ..... -- - -····---.-,--. o --• .. .,,., •-••-•n -- - -· -·-. --·. ·---
Total Psychotropic Utilization l 80 : 70 I
,---••••-••--•• --•-•-• ,.,, .. ,, .. .._,__. ,,..__.., ___ ,,-.--•--•-••-.-•••• ........ ,,, •♦ 0 •o•o ... -..-• .--,,•--•·••• ••"'l••U
; 60
I so
40 -·····-····· .. · -· - - ---.. • --· .. - ·-·---· -----·- .... .... _ --
30 -----.. --,·-----------------· --·-·------ "---··- ·-
20 ·-·---- __________ ,.,. ... ,.--.. ···-.. -·-•-"·----···-·-·--· ..... _____ ,_.� ... -- ··-··-- ·
10 ,,,,,,_.,,, ,.,_,. . .,.,. ,,.,,.._,.-,,..,,. """'" ---••�•-"-"• •••••• .. ••••"""""·'"-•••u-.. •• •••"-••· ••• "" - - -• ""
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
-2019 :;c ·,:·c .. ,2020 -StateAvg -NationAvg
Addendum 9
A-9
Addendum 10
A-10
Addendum 11
A-11
AA-11
A-11
Addendum 12
A-12
Addendum 13
A-12A-13
A-13
Michael Donohue, Pharm.D
President
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
File details come from the government source that posted it. Updated .